Table 2.

Baseline Characteristics of Eligible Patients in Mayo Validation Cohort Who Received Second-Line Treatment

Characteristic	Patient Count (n = 508), n (%)
Age at second-line treatment in years
≤65	245 (48)
66–74	148 (29)
75–79	77 (15)
80+	38 (7)
Sex
Female	144 (28)
Male	364 (72)
Type of first-line treatment received
Chemo-immunotherapy (CIT)	295 (58)
Chemotherapy alone	148 (29)
Immunotherapy alone	59 (12)
Missing	6 (1)
Interval between end of first-line therapy and start of second-line therapy
6 mo to <2 y	275 (54)
2 y to <3 y	105 (21)
3+ y	128 (25)
Fluorescence in situ hybridization status
High risk (11q- or 17p-)	52 (10)
Other/favorable	187 (37)
Missing	269 (53)
IGHV mutation status
Unmutated	217 (43)
Mutated	84 (17)
Missing	207 (41)